Tempus AI today
As of 4:00 pm ET
- 52 week range
- $22.89
▼
$79.49
- Target price
- $56.36
Tempus AI Inc. shares NASDAQ: TOPIC The company surged 35% on Tuesday, bringing its market capitalization to $7.5 billion. The gains were driven by sensational news and strong market sentiment highlighting the company’s leadership in integrating artificial intelligence (AI) into healthcare. Specializing in precision medicine, Tempus uses artificial intelligence to provide personalized care solutions and optimize therapeutic development.
Pelosi’s investments draw attention
Tempus drew investor attention for the first time Tuesday following former House Speaker Nancy Pelosi’s routine trading disclosure. On January 14, Pelosi purchased 50 call options on Tempus shares expiring in January 2026 with an exercise price of $20. At the time of the deal, Tempus shares closed just below $32, but by Tuesday the shares had risen to more than $47.
Pelosi’s deals are closely watched because of her track record of making timely investments, and her husband’s ties to venture capital have heightened public and institutional interest. In addition to Tempus, Pelosi also unveiled positions in Vistra and Palo Alto Networks, which posted gains on Tuesday, adding to the excitement around her portfolio.
Revolutionary launch: health app “Olivia”
A more important driver of Tempus’ growth was the announcement of a new AI-powered health app, Olivia. Designed as a personal health concierge, Olivia integrates patient data from more than 1,000 health systems and platforms such as Apple Health and Google Fit. Olivia aims to change the way patients manage their health by centralizing health records and providing AI-generated information.
One of the app’s standout features is the Smart Profile Summary feature, which uses artificial intelligence to synthesize patient data into a comprehensive health overview. AI-powered Notetaker transcribes and summarizes medical appointment notes to ensure clarity and accessibility for patients. Olivia also enables seamless exchange of medical images and health data, helping improve collaboration between healthcare providers.
Eric Lefkofsky, founder and CEO of Tempus, said the Olivia program is a key step in empowering patients to take control of their health journey. Available on iOS and Android, Olivia highlights Tempus’ commitment to using artificial intelligence to improve patient outcomes. Tuesday’s market enthusiasm reflects growing recognition of AI’s transformative potential in healthcare.
Bullish market sentiment
Tempus AI stock forecast today
$56.36
Growth potential 12.84%Moderate purchase
Based on ratings from 12 analysts
| High forecast | $74.00 |
|---|---|
| Average forecast | $56.36 |
| Low forecast | $44.00 |
Tempus AI Stock Forecast Details
Apart from the news of the day, the sentiment around Tempus remains positive. Analysts have assigned a consensus rating of Moderate Buy, with a price target suggesting 18% upside. Institutional investors are also bullish, with $900 million flowing into the stock over the past 12 months, compared with outflows of just $48.7 million. Cathie Wood’s ARK Investment Management holds a 1.5% stake in Tempus worth $135 million, further demonstrating investor confidence .
Strong preliminary financial results
Tempus’ preliminary financial results for the fourth quarter of 2024, announced on January 13, demonstrated the company’s growth trajectory. The company reported revenue of $200.55 million for the quarter, up 35% year over year. Although the company posted a net loss of $75.84 million for the quarter, its earnings per share of -$0.25 beat expectations.
The company projects revenue to exceed $1.23 billion in 2025, driven by its genomics and data services segments. The acquisition of Ambry Genetics, which is expected to be completed by February 2025, is expected to expand its expertise in cancer screening, pediatrics, rare diseases and cardiology. This acquisition will enable Tempus to enhance its balance sheet and AI-powered data infrastructure, further strengthening its leadership in precision medicine.
Institutional support drives growth
The growth of institutional ownership has been a critical component of Tempus’ momentum. With prominent investors like ARK and other institutions holding significant positions, confidence in the company’s long-term potential is clear. The wider market is recognizing the transformative role of artificial intelligence in healthcare, and Tempus is at the forefront of this innovation.
Tempus AI’s strategic moves and innovative technology applications make it a key player in the future of precision medicine, combining artificial intelligence and data analytics to reshape healthcare delivery.
Before you consider Tempus AI, here’s what you need to hear.
MarketBeat tracks Wall Street’s top-rated and best-performing analysts daily and the stocks they recommend to their clients. MarketBeat identified five stocks that top analysts were quietly telling their clients to buy now, before the broader market caught on… and Tempus AI wasn’t on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, the top-rated analysts think these five stocks are Strong Buys.
View five stocks here
Almost everyone loves a strong dividend stock, but a high yield can signal danger. Discover 20 high-yield dividend stocks that pay out an unacceptably high percentage of their profits. Enter your email address to receive this report and avoid the high-yield dividend trap.
Get this free report